Kwality Pharmaceuticals Limited (KPL) reported revenue of ₹162 Cr and net profit of ₹25.62 Cr for the quarter ended 2026-06-30. Figures are parsed from the company's filed results.
KPL fundamentals, Fundamental score 95/100
The statements below are read from Kwality Pharmaceuticals Limited’s filed results, 10 filed quarters and 12 fiscal years on record, consolidated basis. Price-linked ratios are computed at the last close, sector medians across the served universe, ownership from the shareholding pattern, and any cell whose input isn’t on record shows a dash, never an estimate.
Latest: Q1 FY26-27 · filed Aug 10, 2026
Sales CAGR · 3Y+26.1%FY22 → FY25
Sales CAGR · 4Y+2.5%FY21 → FY25
PAT CAGR · 3Y+52.5%FY22 → FY25
PAT CAGR · 4Y−13.4%FY21 → FY25
Price · 1Y—EOD
Price CAGR · 3Y—EOD
Quarterly resultsConsolidated
₹ Cr
Dec2023
Mar2024
Jun2024
Sep2024
Mar2025
Jun2025
Sep2025
Dec2025
Mar2026
Jun2026Latest
YoYlatest
Sales
78.0
92.0
80.0
90.0
116
111
111
123
157
162
+45.6%
61.0
71.0
63.0
70.0
89.8
87.3
85.7
93.5
118
121
+39.0%
Operating profit
17.0
21.0
17.0
20.0
25.9
24.2
25.4
30.0
38.8
41.0
+69.7%
OPM %
21.8%
22.8%
21.3%
22.2%
22.4%
21.7%
22.8%
24.3%
24.7%
25.3%
+3.6 pp
Other income
1.00
-7.00
0.00
0.00
0.77
0.38
0.90
0.53
1.06
0.62
+65.7%
Interest
3.00
3.00
2.00
3.00
2.49
2.76
2.84
2.48
2.89
2.66
-3.6%
Depreciation
5.00
5.00
4.00
5.00
5.09
4.76
4.96
4.82
5.26
4.99
+4.8%
Profit before tax
10.0
6.00
11.0
13.0
19.1
17.0
18.5
22.3
31.7
34.0
+99.6%
Tax %
20.0%
33.3%
27.3%
38.5%
24.1%
30.0%
23.5%
28.4%
20.1%
24.6%
-5.4 pp
Net profit
8.00
4.00
8.00
8.00
14.5
11.9
14.1
16.0
25.3
25.6
+115.0%
EPS (₹)
7.41
4.20
8.06
8.16
13.95
11.49
13.60
15.42
24.39
24.69
+114.9%
One column per filed quarter · ₹ crore · YoY = latest vs the same quarter a year back · EPS restated for bonus/split↔ scroll for earlier quarters
Revenue & net profit trend
last 10 quarters
RevenueNet profit
Revenue & net profit — Consolidated10 quarters
Segment results
Needs segment dataSegment results not parsedPer-segment revenue, EBIT margin and YoY arrive once we parse the segment annexure from the filing.
Forensic checksauto-scanned from the filing
Coming soonForensic checks not connectedAuditor opinion, OCF÷PAT, contingent liabilities, related-party share and working-capital days arrive as we parse the notes-to-accounts + cash-flow statement. Promoter-pledge is already on the Holdings tab.
How results moved the priceEOD reaction on the session the market could trade the filing
Avg absolute result-day move ±20.0%· EPS surprise: no estimates source· 9 earlier quarters have no dated filing on record
Q1'27filed Mon 10 Aug 12:09 · traded that sessiongap +1.3%close +20.0%
